{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:54:49Z","timestamp":1790963689995,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC 011652"],"award-info":[{"award-number":["ZIA BC 011652"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.tranon.2022.101440","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T08:08:46Z","timestamp":1651651726000},"page":"101440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment"],"prefix":"10.1016","volume":"21","author":[{"given":"Xianyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunkai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody J.","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-3227","authenticated-orcid":false,"given":"Rebekah","family":"Landsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebojsa","family":"Skorupan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-0957","authenticated-orcid":false,"given":"Christine","family":"Alewine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tranon.2022.101440_bib0001","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2022.101440_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2021.118967","article-title":"Furin is not required for processing of mesothelin precursor protein","volume":"1868","author":"Joseph","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"issue":"1","key":"10.1016\/j.tranon.2022.101440_bib0003","first-page":"181","article-title":"Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium","volume":"52","author":"Chang","year":"1992","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2022.101440_bib0004","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s42003-020-01464-5","article-title":"Multiple proteases are involved in mesothelin shedding by cancer cells","volume":"3","author":"Liu","year":"2020","journal-title":"Commun. Biol."},{"issue":"9","key":"10.1016\/j.tranon.2022.101440_bib0005","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1055-9965.EPI-06-0479","article-title":"Mesothelin is shed from tumor cells","volume":"15","author":"Ho","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"4","key":"10.1016\/j.tranon.2022.101440_bib0006","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1515\/cclm.2011.816","article-title":"Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers","volume":"50","author":"Sharon","year":"2012","journal-title":"Clin. Chem. Lab Med."},{"issue":"34","key":"10.1016\/j.tranon.2022.101440_bib0007","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: ready for Prime Time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.tranon.2022.101440_bib0008","doi-asserted-by":"crossref","first-page":"26744","DOI":"10.18632\/oncotarget.15814","article-title":"Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma","volume":"8","author":"Inaguma","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.tranon.2022.101440_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040397","article-title":"Mesothelin Expression in Human Tumors: a Tissue Microarray Study on 12,679 Tumors","volume":"9","author":"Weidemann","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.tranon.2022.101440_bib0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.tranon.2022.101440_bib0011","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1373\/jalm.2017.025015","article-title":"Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer","volume":"3","author":"Yu","year":"2018","journal-title":"J. Appl. Lab Med."},{"key":"10.1016\/j.tranon.2022.101440_bib0012","article-title":"Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma","volume":"2018","author":"Cao","year":"2018","journal-title":"JCO Precision Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2022.101440_bib0013","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","article-title":"Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis","volume":"124","author":"Hassan","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.tranon.2022.101440_bib0014","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.PANCA19-PR07","article-title":"Phase I\/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with nab-paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma","author":"Alewine","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.tranon.2022.101440_bib0015","first-page":"5151","article-title":"Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P","volume":"32","author":"Zhang","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tranon.2022.101440_bib0016","article-title":"Mesothelin enhances tumor vascularity in newly forming pancreatic peritoneal metastases","author":"Avula","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"4","key":"10.1016\/j.tranon.2022.101440_bib0017","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"MESOMARK: a potential test for malignant pleural mesothelioma","volume":"53","author":"Beyer","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/j.tranon.2022.101440_bib0018","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"17099","article-title":"Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors","volume":"104","author":"Zhang","year":"2007"},{"issue":"1","key":"10.1016\/j.tranon.2022.101440_bib0019","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"issue":"24","key":"10.1016\/j.tranon.2022.101440_bib0020","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.1158\/1078-0432.CCR-08-0324","article-title":"High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy","volume":"14","author":"Zhang","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.tranon.2022.101440_bib0021","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1535-7163.MCT-15-0863","article-title":"Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins","volume":"15","author":"Awuah","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"17","key":"10.1016\/j.tranon.2022.101440_bib0022","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1158\/0008-5472.CAN-11-0466","article-title":"Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding","volume":"71","author":"Zhang","year":"2011","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.tranon.2022.101440_bib0023","first-page":"252","article-title":"Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE\/ADAM17-cleaved Amphiregulin in breast cancer","volume":"4","author":"Lofgren","year":"2021","journal-title":"Antib. Ther."},{"issue":"22","key":"10.1016\/j.tranon.2022.101440_bib0024","doi-asserted-by":"crossref","first-page":"19118","DOI":"10.18632\/oncotarget.4078","article-title":"MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism","volume":"6","author":"Shukla","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.tranon.2022.101440_bib0025","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.7150\/thno.42441","article-title":"3D approaches to model the tumor microenvironment of pancreatic cancer","volume":"10","author":"Tomas-Bort","year":"2020","journal-title":"Theranostics"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523322000997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523322000997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:21:51Z","timestamp":1761844911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523322000997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":25,"alternative-id":["S1936523322000997"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2022.101440","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2022.101440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101440"}}